Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Early Access Program (EAP) of avacopan in patients with GPA or MPA treated beyond 52 weeks

Next Previous
Search
Trial Profile

An Early Access Program (EAP) of avacopan in patients with GPA or MPA treated beyond 52 weeks

Status: Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 25 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avacopan (Primary)
  • Indications Granulomatosis with polyangiitis; Microscopic polyangiitis
  • Focus Adverse reactions; Expanded access

    • Most Recent Events

    • 25 Jul 2024 New trial record
    • 15 Jun 2024 Results (n=59) of an analysis reporting safety data in patients treated beyond 52 weeks presented at the 25th Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top